Previous 10 | Next 10 |
– Collaboration to Explore Liver Cell Targets Using Dicerna’s GalXC™ Technology With the Potential to Deliver a Significant Number of Clinical Candidates – – Each Company to Retain Rights to Co-Develop and Co-Commercialize Product Candidates – ...
Dicerna™ Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, w...
Dicerna Pharmaceuticals ( DRNA ) is a biotech that should be on everyone's radar. That's because it recently announced a partnership to develop a hepatitis B product with Roche ( RHHBY ). The hepatitis B indication is a big market opportunity. What makes the deal a good one is that Dicerna...
Dicerna Pharmaceuticals, Inc. (DRNA) Q3 2019 Earnings Conference Call November 7, 2019 4:30 P.M. ET Company Participants Lauren Stival - Investor Relations Doug Fambrough - President and Chief Executive Officer Jack Green - Chief Financial Officer Ralf Rosskamp - Chief Medical ...
Image source: The Motley Fool. Dicerna Pharmaceuticals Inc (NASDAQ: DRNA) Q3 2019 Earnings Call Nov 7, 2019 , 4:30 p.m. ET Operator Continue reading
The following healthcare companies have file for mixed shelf offerings: More news on: Adamas Pharmaceuticals, Inc., Dicerna Pharmaceuticals, Inc., Healthcare stocks news, Read more ...
Dicerna Pharmaceuticals (NASDAQ: DRNA ): Q3 GAAP EPS of -$0.45 misses by $0.17 . More news on: Dicerna Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
— Initiated Dosing of Patients With Primary Hyperoxaluria Types 1 and 2 in PHYOX™2 Pivotal Clinical Trial — — Announced Collaboration Agreement With Roche for Development of DCR-HBVS Including Option to Co-Fund Pivotal Development and Co-Promote in the U.S. ...
Biotech Pulse Biotech finally has a pulse. The improving appetite for risk has resuscitated the moribund biotechs and pharma (biopharma) groups. The Nasdaq Biotech ( IBB ) and the S&P Biotech ( XBI ) indexes have begun their advance from their year-to-date lows recorded earlier in Octo...
Dicerna™ Pharmaceuticals, Inc. (Nasdaq:DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company will release its third quarter 2019 financial results afte...
News, Short Squeeze, Breakout and More Instantly...
Dicerna Pharmaceuticals Inc. Company Name:
DRNA Stock Symbol:
NASDAQ Market:
Dicerna Pharmaceuticals Inc. Website:
Novo Nordisk today announced that the acquisition of Dicerna Pharmaceuticals, Inc. (Dicerna; Nasdaq: DRNA), announced on 18 November 2021, has been completed. Following the expiration of Novo Nordisk’s cash tender offer for Dicerna, Novo Nordisk has today acquired all outstan...
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (“HSR”), in connection with Novo Nordisk’s cash tender offer for Dicerna expired at 11:59 p.m., Easter...
Direxion Launches mRNA ETF (MSGR) MSGR Offers Exposure to Rapidly Evolving mRNA Sector PR Newswire NEW YORK , Dec. 9, 2021 /PRNewswire/ -- Direxion announced today the launch of the Direxion mRNA ETF (Ticker: MSGR) . MSGR invests in companies ...